1. Home
  2. PAYC vs UTHR Comparison

PAYC vs UTHR Comparison

Compare PAYC & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PAYC
  • UTHR
  • Stock Information
  • Founded
  • PAYC 1998
  • UTHR 1996
  • Country
  • PAYC United States
  • UTHR United States
  • Employees
  • PAYC N/A
  • UTHR N/A
  • Industry
  • PAYC Computer Software: Prepackaged Software
  • UTHR Biotechnology: Pharmaceutical Preparations
  • Sector
  • PAYC Technology
  • UTHR Health Care
  • Exchange
  • PAYC Nasdaq
  • UTHR Nasdaq
  • Market Cap
  • PAYC 14.6B
  • UTHR 14.4B
  • IPO Year
  • PAYC 2014
  • UTHR 1999
  • Fundamental
  • Price
  • PAYC $224.07
  • UTHR $297.02
  • Analyst Decision
  • PAYC Hold
  • UTHR Buy
  • Analyst Count
  • PAYC 11
  • UTHR 13
  • Target Price
  • PAYC $230.00
  • UTHR $383.08
  • AVG Volume (30 Days)
  • PAYC 647.3K
  • UTHR 551.5K
  • Earning Date
  • PAYC 07-30-2025
  • UTHR 07-30-2025
  • Dividend Yield
  • PAYC 0.68%
  • UTHR N/A
  • EPS Growth
  • PAYC N/A
  • UTHR 18.86
  • EPS
  • PAYC 7.02
  • UTHR 25.10
  • Revenue
  • PAYC $1,913,800,000.00
  • UTHR $2,994,100,000.00
  • Revenue This Year
  • PAYC $10.03
  • UTHR $14.30
  • Revenue Next Year
  • PAYC $9.22
  • UTHR $6.32
  • P/E Ratio
  • PAYC $31.35
  • UTHR $11.79
  • Revenue Growth
  • PAYC 9.87
  • UTHR 19.84
  • 52 Week Low
  • PAYC $140.69
  • UTHR $266.98
  • 52 Week High
  • PAYC $267.76
  • UTHR $417.82
  • Technical
  • Relative Strength Index (RSI)
  • PAYC 35.90
  • UTHR 51.32
  • Support Level
  • PAYC $222.20
  • UTHR $286.68
  • Resistance Level
  • PAYC $236.24
  • UTHR $301.75
  • Average True Range (ATR)
  • PAYC 6.25
  • UTHR 6.73
  • MACD
  • PAYC -0.21
  • UTHR 1.81
  • Stochastic Oscillator
  • PAYC 19.35
  • UTHR 77.16

About PAYC Paycom Software Inc.

Founded in 1998, Paycom is a human capital management software-as-a-service provider addressing customer requirements surrounding payroll, talent acquisition, talent management, HR management, as well as time and labor. The company primarily services midsize businesses within the United States, targeting businesses with 50-10,000 employees. The company primarily generates revenue through the sale of subscriptions providing access to its HCM platform. To a lesser extent, the company also generates revenue from implementation services provided to customers as well as interest income generated from customer funds. As of fiscal 2024, the company serviced slightly over 37,500 customers and stored data on over 7 million employees.

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.

Share on Social Networks: